Dealing with pre-existing chronic neutropenia in cancer patients—considerations and consequences in the clinical praxis

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Dealing with pre-existing chronic neutropenia in cancer patients—considerations and consequences in the clinical praxis. / Thinggaard, Anna Birgitte; Liposits, Gabor; Fristrup, Niels.

In: ecancermedicalscience, Vol. 14, 1131, 10.2020.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{95b00942053a484bbd71e8c7cdaf0557,
title = "Dealing with pre-existing chronic neutropenia in cancer patients—considerations and consequences in the clinical praxis",
abstract = "Chronic neutropenia is a rare but important challenge with substantial clinical implications for patients receiving antineoplastic treatment. Treatment-induced neutropenia is a well-known adverse event during chemotherapy and some targeted treatments. Guidelines for administering chemotherapy are rather strict to protect the patient from severe and life-threatening complications. Consequently, patients with chronic neutropenia may receive suboptimal antineoplastic treatment. Autoimmune neutropenia or chronic idiopathic neutropenia (CIN) may affect the antineoplastic treatment by causing delayed drug delivery, dose reductions and early discontinuation of treatment. CIN is characterised by the onset in late childhood or adulthood, affects mostly women, is clinically benign and has rare spontaneous remission. Here, we elucidate the challenges related to chronic neutropenia when administering chemotherapy through two clinical cases. Guidelines may need to be revised in order to optimise the treatment of patients with asymptomatic chronic neutropenia, thus personalising the medical decisions for each patient.",
keywords = "Autoimmune neutropenia, Chemotherapy, Chronic idiopathic neutropenia, Chronic neutropenia, Monoclonal antibodies, Targeted therapy",
author = "Thinggaard, {Anna Birgitte} and Gabor Liposits and Niels Fristrup",
year = "2020",
month = oct,
doi = "10.3332/ECANCER.2020.1131",
language = "English",
volume = "14",
journal = "ecancermedicalscience",
issn = "1754-6605",
publisher = "ecancer Global Foundation",

}

RIS

TY - JOUR

T1 - Dealing with pre-existing chronic neutropenia in cancer patients—considerations and consequences in the clinical praxis

AU - Thinggaard, Anna Birgitte

AU - Liposits, Gabor

AU - Fristrup, Niels

PY - 2020/10

Y1 - 2020/10

N2 - Chronic neutropenia is a rare but important challenge with substantial clinical implications for patients receiving antineoplastic treatment. Treatment-induced neutropenia is a well-known adverse event during chemotherapy and some targeted treatments. Guidelines for administering chemotherapy are rather strict to protect the patient from severe and life-threatening complications. Consequently, patients with chronic neutropenia may receive suboptimal antineoplastic treatment. Autoimmune neutropenia or chronic idiopathic neutropenia (CIN) may affect the antineoplastic treatment by causing delayed drug delivery, dose reductions and early discontinuation of treatment. CIN is characterised by the onset in late childhood or adulthood, affects mostly women, is clinically benign and has rare spontaneous remission. Here, we elucidate the challenges related to chronic neutropenia when administering chemotherapy through two clinical cases. Guidelines may need to be revised in order to optimise the treatment of patients with asymptomatic chronic neutropenia, thus personalising the medical decisions for each patient.

AB - Chronic neutropenia is a rare but important challenge with substantial clinical implications for patients receiving antineoplastic treatment. Treatment-induced neutropenia is a well-known adverse event during chemotherapy and some targeted treatments. Guidelines for administering chemotherapy are rather strict to protect the patient from severe and life-threatening complications. Consequently, patients with chronic neutropenia may receive suboptimal antineoplastic treatment. Autoimmune neutropenia or chronic idiopathic neutropenia (CIN) may affect the antineoplastic treatment by causing delayed drug delivery, dose reductions and early discontinuation of treatment. CIN is characterised by the onset in late childhood or adulthood, affects mostly women, is clinically benign and has rare spontaneous remission. Here, we elucidate the challenges related to chronic neutropenia when administering chemotherapy through two clinical cases. Guidelines may need to be revised in order to optimise the treatment of patients with asymptomatic chronic neutropenia, thus personalising the medical decisions for each patient.

KW - Autoimmune neutropenia

KW - Chemotherapy

KW - Chronic idiopathic neutropenia

KW - Chronic neutropenia

KW - Monoclonal antibodies

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85096436069&partnerID=8YFLogxK

U2 - 10.3332/ECANCER.2020.1131

DO - 10.3332/ECANCER.2020.1131

M3 - Journal article

AN - SCOPUS:85096436069

VL - 14

JO - ecancermedicalscience

JF - ecancermedicalscience

SN - 1754-6605

M1 - 1131

ER -